[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336823-105":59,"doc-detail-336823-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","naprt-silencing-in-fh-deficient-renal-cell-carcinoma-confers-therapeutic-vulnerabilities-via-nad-depletion","NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion","","Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) results from fumarate hydratase (FH) loss, which drives an aggressive renal cell carcinoma state through fumarate accumulation and widespread cellular disruption. Patterns of hypermethylation in FH-mutant cell lines and tumor samples link to silencing of NAPRT, a rate-limiting enzyme in NAD+ biosynthesis. FH-deficient models with NAPRT loss, and other NAPRT-silencing cancers, show extreme sensitivity to NAMPT inhibitors, with synergy from PARP inhibitors via effects on PAR-mediated DNA repair.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/naprt-silencing-in-fh-deficient-renal-cell-carcinoma-confers-therapeutic-vulnerabilities-via-nad-depletion/336823/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/naprt-silencing-in-fh-deficient-renal-cell-carcinoma-confers-therapeutic-vulnerabilities-via-nad-depletion/336823.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What causes hereditary leiomyomatosis and renal cell carcinoma (HLRCC)?","Question",{"text":112,"@type":113},"HLRCC is caused by loss-of-function mutations in the fumarate hydratase (FH) gene, leading to aggressive FH-deficient renal cell carcinomas.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does NAPRT relate to NAD+ metabolism in this study?",{"text":117,"@type":113},"NAPRT is a rate-limiting enzyme in the Preiss–Handler pathway of NAD+ biosynthesis, and its silencing reduces NAPRT expression.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment vulnerabilities are associated with NAPRT silencing?",{"text":121,"@type":113},"FH-deficient RCC models with NAPRT silencing are extremely sensitive to NAMPT inhibitors, and NAPRT silencing also shows synergistic tumor cell killing with PARP inhibitors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336823,1790966769,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion  \nKatelyn J. Noronha1, Karlie N. Lucas2, Sateja Paradkar3, Joseph Edmonds2, Sam Friedman2, Matthew A. Murray3, Samantha Liu2, Dipti P. Sajed4, Chana Sachs4, Josh Spurrier5, Mitch Raponi5, Jiayu Liang6, Hao Zeng6, Ranjini K. Sundaram2, Brian Shuch7, Juan C. Vasquez8,  \nand Ranjit S. Bindra2  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is caused by loss of function mutations in fumarate hydratase (FH) and results in an aggressive subtype of renal cell carcinoma with limited treatment options. Loss of FH leads to accumulation of fumarate, an oncometabolite that disrupts multiple cellular processes and drives tumor progression. High levels of fumarate inhibit alpha ketoglutarate-dependent dioxygenases, includingthe ten–eleven translocation (TET) enzymes, and can lead to global DNA hypermethylation. Here, we report patterns of hypermethylation in FH-mutant cell lines and tumor samples are associated with the silencing of nicotinate phosphoribosyl transferase (NAPRT), a rate-limiting enzyme in the Preiss– Handler pathway of NAD+ biosynthesis, in a subset of HLRCC cases. NAPRT is hypermethylated at a CpG island in the promoter in cell line models and patient samples, resulting in loss of NAPRT expression. We find that FH-deficient RCC models with\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | loss of NAPRT expression, as well as other oncometaboliteproducing cancer models that silence NAPRT, are extremely sensitive to nicotinamide phosphoribosyl transferase inhibitors (NAMPTi) . NAPRT silencing was also associated with synergistic tumor cell killing with PARP inhibitors and NAMPTis, which was associated with effects on PAR-mediated DNA repair. Overall, our findings indicate that NAPRT silencing can be targeted in oncometabolite-producing cancers and elucidates how oncometabolite-associated hypermethylation can impact diverse cellular processes and lead to therapeutically relevant vulnerabilities in cancer cells.\u003Cbr>Implications: NAPRT is a novel biomarker for targeting NAD+ metabolism in FH-deficient HLRCCs with NAMPTis alone and targeting DNA repair processes with the combination of NAMPTis and PARP inhibitors. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nHereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare inherited cancer syndrome characterized by germline mutation and subsequent loss of heterozygosity of the fumarate hydratase (FH) gene. HLRCC leads to the development of FH-deficient RCCs,  \n1Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut. 2Department of Therapeutic Radiology, Yale University, New Haven, Connecticut. 3Department of Experimental Pathology, Yale University, New Haven, Connecticut. 4Department of Pathology, Univers","cbCaif0RX8zK6XoS","https://ap.wps.com/l/cbCaif0RX8zK6XoS","pdf",5632059,16,"English","# Introduction\n## HLRCC and FH-deficient RCC background\n## Oncometabolites and disrupted TCA cycle\n## Therapeutic implications and targeted vulnerability","[{\"question\":\"What causes hereditary leiomyomatosis and renal cell carcinoma (HLRCC)?\",\"answer\":\"HLRCC is caused by loss-of-function mutations in the fumarate hydratase (FH) gene, leading to aggressive FH-deficient renal cell carcinomas.\"},{\"question\":\"How does NAPRT relate to NAD+ metabolism in this study?\",\"answer\":\"NAPRT is a rate-limiting enzyme in the Preiss–Handler pathway of NAD+ biosynthesis, and its silencing reduces NAPRT expression.\"},{\"question\":\"What treatment vulnerabilities are associated with NAPRT silencing?\",\"answer\":\"FH-deficient RCC models with NAPRT silencing are extremely sensitive to NAMPT inhibitors, and NAPRT silencing also shows synergistic tumor cell killing with PARP inhibitors.\"}]","NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion | PDF",1790016746,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55778cbc7c751cd439861aed64ae03eb.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4becefeb35699463dc9f3366d2f9198.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7629f1c7c1123b18211a15c25c55ff4.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc2945cc2a153f150622f71e3eaba723.webp",980,1311]